InfuSystem (INFU) Q4 2025: Gross Margin Expands 260bps as Wound Care and PCDs Fuel Mix Shift
InfuSystem’s Q4 2025 results spotlight a decisive margin expansion, propelled by operational discipline, a wind-down of low-return contracts, and accelerating mix shift in wound care and pneumatic compression devices (PCDs). Management’s focus on scalable, capital-light revenue streams and a technology-driven operating model sets the stage for continued profitability, even as topline growth moderates in 2026. Execution on new product launches and cost containment will be critical levers for outperformance as the year unfolds.
Summary
- Margin Expansion Through Mix Shift: Operational discipline and wound care growth drove gross margin gains.
- Strategic Exit of Low-Margin Contract: Shedding the GE Healthcare contract improves profitability profile in 2026.
- Tech-Driven Productivity: ERP and revenue cycle upgrades position INFU for scalable, capital-efficient growth.
Performance Analysis
InfuSystem delivered a 7% year-over-year revenue increase in Q4 2025, with both Patient Services and Device Solutions contributing to growth. Patient Services, the larger segment, saw a 5.4% revenue lift, underpinned by higher volumes in oncology and a standout 160% surge in wound care, largely due to the recent launch of pneumatic compression devices (PCDs, devices aiding circulation). Device Solutions posted a 9.7% gain, driven by higher equipment sales and a more diversified biomedical services client base, offset by a reduction in equipment rental revenue.
Gross profit rose 12% year-over-year, with gross margin expanding to just over 56%, up 260bps. This improvement reflected increased labor efficiency, a favorable revenue mix shift toward higher-margin categories like oncology, and lower procurement and maintenance costs. Selling, general, and administrative expenses rose 6.5%, mainly due to ERP (enterprise resource planning, core business software) project costs and incremental headcount to support growth. Adjusted EBITDA set a new quarterly record, with margin climbing above 24%, reflecting the company’s ability to scale profitably even as it invests in technology and product launches.
- Wound Care Inflection: PCDs fueled over 160% revenue growth in wound care, signaling successful new product ramp.
- Capital Efficiency Gains: Net capital expenditures halved year-over-year as growth shifted to less asset-intensive lines.
- Cash Flow Strength: Operating cash flow rose 19% for the year, supporting buybacks and debt reduction.
The company’s exit from its largest low-margin biomedical contract (GE Healthcare) will reduce revenue by $7.1 million annually, but with an even larger expense reduction, positioning INFU for higher profitability in 2026. The balance sheet remains robust, with net debt to EBITDA at 0.52x and $58 million in liquidity, enabling flexibility for opportunistic buybacks and future M&A.
Executive Commentary
"We continue to make advances on key initiatives that are expected to help us accelerate our growth rate of net revenue, adjusted EBITDA, and operating cash flows during 2026... This important initiative allows us to reduce processing costs and expand our volume capacity, thereby opening the door to increased revenue volume."
Kerry LaChance, Chief Executive Officer
"Adjusted EBITDA during the 2025 fourth quarter was $8.8 million... These amounts included the spending on the ERP project, which again, is expected to start to decrease by the second quarter here in 2026. For the full year of 2025, adjusted EBITDA totaled $31.5 million, representing a margin of 21.9, an increase of 3.1% from 18.8% in 2024. This reflects a significant year-over-year improvement of $6.2 million, or 24.3%, despite a $1.8 million increase in ERP project expenses."
Barry Steele, Chief Financial Officer
Strategic Positioning
1. Business Model Evolution Toward Capital-Light Growth
INFU’s focus is shifting from capital-intensive equipment rentals toward higher-margin, scalable services and product categories. The company’s Patient Services segment, anchored by oncology and expanding wound care, is now the primary growth engine. The recent PCD launch and new DME (durable medical equipment, home-use medical devices) accreditations highlight a commitment to portfolio expansion with lower capital requirements.
2. Operational Leverage from Tech Investments
ERP and revenue cycle management (RCM, billing and collections systems) upgrades are central to INFU’s margin improvement and future scalability. The completed migration of wound care to the new RCM platform has already enabled faster onboarding and higher throughput, with oncology set to follow in the second half of 2026. The ERP rollout, going live in Q1 2026, is expected to drive $2 million in annualized cost savings and unlock further productivity gains across departments.
3. Strategic Pruning and Margin Focus
The restructuring and exit of the GE Healthcare biomedical contract reflects a deliberate pivot away from low-return volume. While this reduces topline by 5.5%, management expects a larger drop in related expenses, with cost savings flowing directly into gross margin. The biomed field team was also right-sized to match new volume expectations and focus on more profitable, smaller engagements.
4. Product Pipeline and Portfolio Expansion
INFU is leveraging new product accreditations and manufacturer partnerships to diversify its DME offerings. Early traction with Defender Boot and Hydrawear in the ostomy category, alongside expansion of PCDs, signals a pipeline approach—testing reimbursement and market fit before scaling. Management is cautious on setting expectations, but sees these as incremental growth levers.
5. Capital Allocation Discipline
Share repurchases, debt paydown, and M&A remain core capital allocation levers. Management reiterated its opportunistic buyback stance, supported by strong free cash flow and a flexible revolving credit facility. With leverage low and liquidity ample, INFU retains optionality to pursue accretive acquisitions or reinvest in high-return internal initiatives.
Key Considerations
This quarter marks a pivotal transition for INFU as it leans into technology-driven efficiency, exits unprofitable volume, and builds a platform for higher-margin, scalable growth.
Key Considerations:
- Wound Care and PCDs as Growth Catalysts: Sustained momentum in these areas could drive upside to guidance, especially as the new RCM system enables faster volume ramp.
- Margin Sustainability: The ability to hold or improve gross and EBITDA margins as inflationary headwinds persist will be a central investor focus.
- ERP Payback and Productivity: Realizing the projected $2 million in annualized savings and further automation benefits is critical for cost structure improvement.
- Portfolio Diversification: Success in new DME categories could de-risk the business and open additional channels for growth.
- Capital Allocation Flexibility: Maintaining a balance between buybacks, debt management, and selective M&A will be key to long-term value creation.
Risks
Execution risk remains around the integration and productivity gains from new technology platforms, as well as the commercialization of new DME products. Inflationary pressures on healthcare costs and potential delays in CMS reimbursement decisions (e.g., chemo mouthpiece) could impact margin trajectory. The company’s reliance on continued oncology and wound care growth introduces concentration risk, while competitive dynamics in biomedical services and DME may pressure pricing or volumes if not offset by innovation and operational excellence.
Forward Outlook
For Q1 2026, INFU expects:
- ERP project costs to peak, then decline sharply post go-live.
- Revenue growth to reflect the GE Healthcare contract exit, with underlying growth in core segments.
For full-year 2026, management guided to:
- Annual revenue growth of 6% to 8% (pro forma for contract exit)
- Adjusted EBITDA margin in the mid to low 20% range, inclusive of ongoing IT upgrade costs
Management highlighted several factors that will shape the year:
- Upside potential from new product launches and CMS reimbursement approvals not included in low-end guidance
- Cost savings from ERP and biomed restructuring expected to fully materialize by Q2
Takeaways
INFU’s Q4 2025 results underscore a business in transformation, moving beyond legacy, low-margin contracts to embrace scalable, tech-enabled service growth and disciplined cost management.
- Margin Expansion: The exit from the GE Healthcare contract and operational improvements drove a step-change in gross and EBITDA margins, providing a higher baseline for 2026.
- Technology as a Force Multiplier: Success with the new RCM and ERP platforms is enabling volume growth without commensurate cost increases, positioning INFU for operating leverage.
- Product and Portfolio Optionality: Execution on new DME product launches and further wound care ramp represent key watchpoints for incremental upside in 2026 and beyond.
Conclusion
InfuSystem enters 2026 with a streamlined portfolio, improved margin structure, and a technology-driven operating model. Sustained execution on new product launches, cost containment, and capital-light growth will be the critical levers as the company navigates a pivotal year of transition and potential acceleration.
Industry Read-Through
INFU’s results reinforce several sector-wide themes: the shift toward capital-light, recurring-revenue models in healthcare services, the importance of technology-driven operational leverage, and the necessity of pruning low-return contracts to protect margin. The success of PCD and wound care launches signals continued demand for home-based, value-add DME solutions, while ERP and RCM investments highlight the competitive necessity of digital infrastructure. Other device and service providers should note the margin and cash flow impact of portfolio optimization and disciplined capital allocation, as well as the strategic advantage of scalable, tech-enabled platforms in a consolidating landscape.